HealthQuill Pharma
British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal of the radiographic progression-free survival target in test patients.
Drugs Health Pharma

AstraZeneca stops prostate cancer trial, Q1 revenue up 10% to $13.6b

HQ Team April 29, 2025: British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal.

Read More
Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to add rare tumour therapies to its portfolio.
Drugs Medical Pharma

Merck to buy SpringWorks for $3.9b to add rare tumour medicines

HQ Team April 29, 2025: Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to.

Read More
Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in the European Union of an oral drug for Duchenne muscular dystrophy in patients six years or older, who can walk.
Drugs Medical Pharma

Italfarmaco gets conditional marketing nod in EU for DMD drug

HQ Team April 27, 2025: Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in.

Read More
The European Medicines Agency has granted a marketing authorisation in the EU for Amgen Inc.’s medicine for treating thyroid eye disease, according to a statement.
Drugs Medical Pharma

Amgen’s thyroid eye disease medicine gets EU market authorisation

HQ Team April 27, 2025: The European Medicines Agency has granted a marketing authorisation in the EU for Amgen Inc.’s medicine for treating.

Read More
Johnson & Johnson’s investigational treatment to help people with a specific type of early-stage bladder cancer has shown 80% of the patients to be free of cancer for up to nine months, and 94% were able to avoid surgical removal of the organ after a year of follow-up.
Drugs Health Pharma

J&J’s trial drug for a type of bladder cancer helps avoid organ removal 

HQ Team April 27, 2025: Johnson & Johnson’s investigational treatment to help people with a specific type of early-stage bladder cancer has shown.

Read More
Uganda declared the Ebola disease outbreak, which started three months ago, has ended, according to the World Health Organization.
Drugs Health Pharma

Uganda declares Ebola disease outbreak to be over, WHO says

HQ Team April 26, 2025: Uganda declared the Ebola disease outbreak, which started three months ago, has ended, according to the World Health.

Read More
Amgen Inc. will expand its Ohio biomanufacturing facility for $900 million, after a recent move to invest $1 billion to build a second manufacturing plant in Holly Springs, North Carolina, US.
Drugs Medical Pharma

Amgen to invest $900 million in Ohio biomanufacturing facility

HQ Team April 26, 2025: Amgen Inc. will expand its Ohio biomanufacturing facility for $900 million, after a recent move to invest $1 billion to.

Read More
UNOPS stands for the United Nations Office for Project Services. It is a UN agency that implements humanitarian and development projects for the UN system, international financial institutions, and other partners. UNOPS provides infrastructure, procurement, and project management services to support peace and security, humanitarian, and development initiatives globally.
Drugs Health Pharma

UN body cuts price of medicine to combat multidrug-resistant TB

HQ Team April 23, 2025: A UN agency, the Stop TB Partnership’s Global Drug Facility (GDF), cut the price of pretomanid, a key.

Read More
Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms in patients who are already on regular medication.
Drugs Health Pharma

Bristol Myers’ oral medication for schizophrenia fails to meet main goal

HQ Team April 23: Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms.

Read More
Swiss healthcare multinational F. Hoffmann-La Roche AG will invest $50 billion in the US over the next five years to expand its research and manufacturing facilities.
Drugs Medical Pharma

Roche to invest $50 billion in US over next five years to expand capacity

HQ Team April 22, 2025: Swiss healthcare multinational F. Hoffmann-La Roche AG will invest $50 billion in the US over the next five.

Read More